Effect of severe left ventricular systolic dysfunction on hospital outcome after transcatheter aortic valve implantation or surgical aortic valve replacement: Results from a propensity-matched population of the Italian OBSERVANT multicenter study  by Onorati, Francesco et al.
Acquired Cardiovascular Disease Onorati et al
A
C
DEffect of severe left ventricular systolic dysfunction on hospital
outcome after transcatheter aortic valve implantation or surgical
aortic valve replacement: Results from a propensity-matched
population of the Italian OBSERVANT multicenter studyFrancesco Onorati, MD, PhD,a Paola D’Errigo, MSc,b Claudio Grossi, MD,c Marco Barbanti, MD,d
Marco Ranucci, MD,e Daniel Remo Covello, MD,f Stefano Rosato, MSc,b Alice Maraschini, MSc,b
Gennaro Santoro, MD,g Corrado Tamburino, MD,d Fulvia Seccareccia, MSc,b Francesco Santini, MD,h and
Lorenzo Menicanti, MD,e on behalf of the OBSERVANT Research GroupFrom th
Italy;
tituto
S. Cr
Hosp
Found
Anest
clinic
and I
Careg
Hosp
Disclosu
Read at
Coeu
Receive
public
Address
versit
0022-52
Copyrig
http://dx
568Objective: Despite demonstration of the superior outcomes of transcatheter aortic valve implantation (TAVI)
versus optimal medical therapy for severe left ventricular systolic dysfunction, studies comparing TAVI and sur-
gical aortic valve replacement (AVR) in this high-risk group have been lacking.
Methods:Weperformedpropensitymatching for age, gender, baseline comorbidities, previous interventions, priority
at hospital admission, frailty score, NewYorkHeart Association class, EuroSCORE, and associated cardiac diseases.
Next, the 30-day mortality and procedure-related morbidity of 162 patients (81 TAVI vs 81 AVR) with severe left
ventricular systolic dysfunction (ejection fraction  35%) were analyzed at the Italian National Institute of Health.
Results: The 30-day mortality was comparable (P¼ .37) between the 2 groups. The incidence of periprocedural
acute myocardial infarction (P¼ .55), low output state (P¼ .27), stroke (P¼ .36), and renal dysfunction (peak
creatinine level, P ¼ .57) was also similar between the 2 groups. TAVI resulted in significantly greater postpro-
cedural permanent pacemaker implantation (P ¼ .01) and AVR in more periprocedural transfusions (P<.01)
despite a similar transfusion rate per patient (2.8  3.7 for TAVI vs 4.4  3.8 for AVR; P ¼ .08). The postpro-
cedural intensive care unit stay (median, 2 days after TAVI vs 3 days after AVR; P¼ .34), intermediate care unit
stay (median, 0 days after both TAVI and AVR; P¼ .94), and hospitalization (median, 11 days after TAVI vs 14
days after AVR; P ¼ .51) were comparable.
Conclusions: In patients with severe left ventricular systolic dysfunction, both TAVI and AVR are valid treat-
ment options, with comparable hospital mortality and periprocedural morbidity. Comparisons of the mid- to
long-term outcomes are mandatory. (J Thorac Cardiovasc Surg 2014;147:568-75)The coexistence of severe aortic stenosis (SAS) and severe
left ventricular systolic dysfunction (SLVSD) significantly
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The Journal of Thoracic and Cardiovascular Surgof surgical aortic valve replacement (AVR) according to
both the EuroSCORE and the Society of Thoracic Sur-
geons score.1 Although AVR still represents the reference
standard to cure SAS in the presence of SLVSD because of
the demonstrated survival benefit in patients without or
with uncertain inotropic reserve,2 the combination of
SLVSD with advanced age and significant comorbidities
could occasionally result in a predicted operative risk great
enough to potentially outweigh the survival benefits of
AVR.3 Accordingly, since the demonstration of the safety
and efficacy of transcatheter aortic valve implantation
(TAVI) to cure SAS in patients at high risk of AVR, the
application of TAVI has widened to include the subset of
patients with SLVSD.4-7 However, contradictory results
have been reported in TAVI studies, with some studies
showing comparable early and long-term outcomes,
regardless of the preoperative systolic left ventricular
function,4,5 some reporting comparable survival but a
greater incidence of major adverse cardiovascular events
in patients with depressed ventricular function,6 and
some showing significantly better left ventricular ejectionery c February 2014
Abbreviations and Acronyms
AMI ¼ acute myocardial infarction
AVR ¼ aortic valve replacement
FRANCE-2 ¼ French Transcatheter Aortic Valve
Intervention
ICU ¼ intensive care unit
ImCU ¼ intermediate care unit
LCOS ¼ low cardiac output syndrome
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PARTNER ¼ Placement of AoRTic TraNscathetER
PPM ¼ permanent pacemaker
SAS ¼ severe aortic stenosis
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Dfraction (LVEF) recovery despite lower 30-day and 1-year
survival of patients with SLVSD.7 Furthermore, most
of these studies were retrospective analyses of single-
center experiences or that of a few centers.4-6 Therefore,
despite the widespread use of TAVI for SLVSD, studies
directly comparing AVR and TAVI in this high-risk cohort
have been lacking, possibly because of the different base-
line risk profile of the TAVI and AVR populations. Finally,
the recent analysis of the Placement of AoRTic TraNscath-
etER (PARTNER) valve trial of patients with low-flow
severe aortic stenosis reported comparable mortality
between high-risk patients randomized to surgical AVR
or TAVI.8 Thus, despite the recent data from randomized
studies suggesting substantial equipoise between AVR
and TAVI in terms of mortality in patients with depressed
ventricular function,8 the results coming from registries—
which mirror ‘‘real-world’’ practice—are still lacking.
Therefore, it was the aim of the present study to investigate
the role of SLVSD on both clinical presentation and hospi-
tal outcomes after TAVI and AVR in a propensity-matched
population. The analysis was performed from a prospec-
tive series of patients enrolled in the Italian National Insti-
tute of Health Observational Multicenter (OBSERVANT)
registry, a prospective registry aimed at evaluating the
efficacy and effectiveness of TAVI versus AVR for the
treatment of severe SAS.9-11
METHODS
Study Design and Population Enrolled
The Italian National Health Institution, in cooperation with the Italian
Ministry of Health, the National Agency for Regional Health Services,
Italian regions, and Italian scientific societies representing the profes-
sionals involved in the treatment of patients with SAS started the Observa-
tional study of appropriateness, efficacy, and effectiveness of AVR-TAVIThe Journal of Thoracic and Caprocedures for the treatment of SAS (OBSERVANT) in January 2011.
Details of the OBSERVANT registry have been previously reported.9,11
In brief, on the basis of established criteria, the study included all symp-
tomatic adult patients admitted to hospitals with a diagnosis of SAS
(defined as an aortic valve area< 1 cm2, maximum aortic velocity> 4
m/s, or mean pressure gradient>40 mm Hg) and requiring an aortic valve
procedure.9,11 Treatment allocation was always from review by the local
multidisciplinary ‘‘heart’’ team involving cardiologists, surgeons, and
anesthesiologists and was in accordance with the established criteria
(clinical evaluation, imaging findings, and risk profile) and current
guidelines.9 Although the treatment allocation stemmed from the local
‘‘heart team’’ evaluation, a greater EuroSCORE, more advanced age,
chronic obstructive pulmonary disease, peripheral arteriopathy, previous
cardiac surgery, greater frailty, advanced New York Heart Association
class, concurrent coronary disease, concurrent moderate or severe mitral
regurgitation, lower gradients despite a similar LVEF, all preferentially
indicated TAVI for the population of patients with a LVEF of 35%.
Thus, all these baseline characteristics were prevalent in the TAVI cohort
(Table 1).
Given the observational nature of the present study, all the percutaneous
and surgical procedures were enrolled, regardless of the prosthesis
employed, the surgical or percutaneous access used, and the periprocedural
management.
Although the enrollment of patients in the OBSERVANT registry ended
in June 2012, the present analysis included the first 12 months of data
collection and focused on all patients with SAS and SLVSD enrolled at
that time. SLVSD was defined by the presence of a preoperative LVEF
of 35% (Simpson method) on the preoperative echocardiogram. For
the purposes of the present study, a porcelain aorta, difficult thoracic
approach, and frailty score of 3 (not self-sufficient) were exclusion criteria,
because they preferentially contraindicated AVR and therefore did not fit
with the propensity-matching analysis. The local ethics committees
approved the study protocol, and all patients enrolled in the database pro-
vided informed consent to the scientific treatment of their data in an anon-
ymous form.9-11
The endpoints of OBSERVANT registry have been previously re-
ported.9,11 In brief, the 30-day mortality was the primary endpoint of the
study.9-11 From previously published data, 30-day mortality has been
recognized to be strictly related to the index procedure to be considered
‘‘real’’ procedural mortality. This was also in accordance with the last
Valve Academic Research Consortium (VARC)-2 definitions.12 The sec-
ondary endpoints were acute myocardial infarction (AMI), stroke, major
vascular complications, cardiac tamponade, transfusions (percentage of
transfused patients; number of transfusions/patient), need for permanent
pacemaker (PPM) implantation, low cardiac output state (LCOS), peak
postoperative creatinine, postprocedural mean transprosthetic gradients
and residual aortic valve regurgitation, and length of hospitalization, inten-
sive care unit (ICU) stay, and intermediate care unit (ImCU) stay, as previ-
ously reported9-11 and in accordance with the guidelines.12 The endpoints
were all adjudicated by 2 independent investigators.10,11Statistical Analysis
All the analyses were performed, stratifying by intervention type (AVR
vs TAVI). To reduce the effect of selection bias and potential confounding
factors, all the outcome parameters were adjusted using the propensity
score method and stepwise logistic regression (probability of
enter¼ 0.20; probability of removal¼ 0.10). Nonparsimonious propensity
score matching was built that included age, gender, weight, preoperative
creatinine, preoperative serum albumin and hemoglobin, diabetes mellitus,
chronic dialysis treatment, previous AMI and unstable angina, chronic
obstructive pulmonary disease and/or preoperative oxygen dependency,
neurologic dysfunction, chronic liver disease, peripheral arteriopathy, pre-
vious cardiac or vascular surgery, frailty score 1 or 2 (geriatric status scale),
previous percutaneous coronary interventions, previous aortic balloonrdiovascular Surgery c Volume 147, Number 2 569
TABLE 1. Baseline characteristics of population with severe left
ventricular systolic dysfunction (LVEF  35%)
Variable
AVR
(n ¼ 169)
TAVI
(n ¼ 180) P value
Demographic and clinical characteristics
Age (y) 73.5  9.1 79.9  8.1 <.01
Female gender 91 (33.8) 63 (35.0) .07
Weight (kg) 74.3  15.4 70.2  18.3 .01
Diabetes 70 (26.0) 59 (32.8) .12
Creatinine (mg/dL) 1.5  1.3 1.5  1.0 .93
Chronic dialysis treatment 9 (3.3) 6 (3.3) .96
Albumin (mg/dL) 3.5  0.9 3.5  0.9 .65
Hemoglobin (mg/dL) 12.4  1.6 11.5  1.7 <.01
Previous AMI 17 (6.3) 10 (5.6) .95
Unstable angina 10 (3.7) 13 (7.2) .10
COPD 22 (8.2) 55 (30.6) <.01
Oxygen dependency 9 (3.3) 14 (7.8) .10
Neurologic dysfunction 11 (4.1) 13 (7.2) .14
Chronic liver disease 6 (2.2) 4 (2.2) .47
Peripheral arteriopathy 30 (11.1) 52 (28.9) .00
Previous cardiac surgery 47 (17.5) 49 (27.2) .01
Previous vascular surgery 7 (2.6) 10 (5.6) .26
Frailty score <.01
1 (self-sufficient) 247 (91.8) 125 (69.4)
2 (partially
self-sufficient)
22 (8.2) 55 (30.6)
Previous PCI 37 (13.7) 65 (36.1) <.01
Previous aortic
balloon plasty
13 (4.8) 43 (23.9) <.01
Critical preoperative state 24 (8.9) 24 (13.3) .14
NHYA class <.01
III 66 (24.5) 92 (51.1)
IV 30 (11.1) 44 (24.4)
Logistic EuroSCORE 15.7  13.3 25.8  18.3 <.01
Angiographic and echocardiographic findings
Coronary artery disease <.01
1-vessel 26 (9.7) 46 (25.6)
2-vessel 12 (4.5) 14 (7.8)
3-vessel 32 (11.9) 20 (11.9)
Left main 0 (0.0) 1 (0.6)
Mitral valve regurgitation <.01
None or mild 222 (82.5) 80 (44.5)
Moderate or severe 47 (17.5) 100 (55.5)
Aortic valve pattern
Valve area (cm2) 0.8  0.3 0.7  0.3 <.01
Peak gradient (mm Hg) 67.5  23.8 61.9  20.8 <.01
Mean gradient (mm Hg) 41.3  15.8 36.9  13.3 <.01
Annulus diameter (cm) 22.1  3.2 22.7  2.4 .06
Procedural characteristics
Urgency status .31
Urgent 12 (4.5) 15 (8.3)
Emergent 5 (1.9) 4 (2.2)
Anesthesia <.01
General 266 (98.9) 62 (34.4)
Epidural or local 2 (0.7) 117 (65.0)
Associated coronary procedure 58 (21.6) 7 (3.9) <.01
(Continued)
TABLE 1. Continued
Variable
AVR
(n ¼ 169)
TAVI
(n ¼ 180) P value
Type of TAVI prosthesis —
CV — 120 (66.7)
ELS — 60 (33.3)
Data presented as mean  standard deviation or n (%). LVEF, Left ventricular ejec-
tion fraction; AVR, aortic valve replacement; TAVI, transcatheter aortic valve implan-
tation; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary
disease; PCI, percutaneous coronary intervention; NYHA, New York Health Associ-
ation; CV, CoreValve; ELS, Edwards SAPIEN valve.
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tic EuroSCORE, associated and extent of coronary artery disease, associ-
ated and degree of mitral valve disease, aortic valve area on
echocardiography, and priority status at admission. Pairs of TAVI and
AVR patients with the same probability score (caliper match with 3-digit
approximation) were matched. Categorical variables are presented as
counts and percentages and were compared with the chi-square test or
Fisher’s exact test, when appropriate. Continuous variables are presented
as the mean  standard deviations and were compared using the Student
t test. The statistical package, STATA, version 11 (StataCorp, College
Station, Tex), was used. P<.05 was considered significant.
RESULTS
Of the 5890 patients prospectively enrolled in the
OBSERVANT registry after 12 months, 458 (7.8%) demon-
strated preoperative SLVSD (LVEF  35%). Thus, only
these 458 patients were considered in the present
propensity-matching analysis. The propensity matching
finally selected 162 propensity-matched patients (81 for
each group). However, the entire population of patients
with SLVSD undergoing TAVI demonstrated significant
differences compared with those undergoing AVR for
most of the preoperative clinical, echocardiographic, and
angiographic characteristics (Table 1). In particular, when
the preoperative echocardiographic and angiographic find-
ings were considered, patients undergoing TAVI had a
greater prevalence of coronary artery disease (in particular,
single-vessel, 2-vessel, and left main disease, although they
underwent fewer concomitant myocardial revascularization
procedures), a greater prevalence of moderate-to-severe
mitral regurgitation, and a lower aortic valve area and lower
peak and mean gradients, despite a trend toward a greater
aortic annular diameter (Table 1). All 458 patients with
SLVSD underwent nonparsimonious propensity matching,
resulting in a comparable cohort of AVR and TAVI patients
(81 pairs) in terms of the baseline characteristics (Table 2).
Nonetheless, among the matched population, the AVR pa-
tients still had a slightly larger aortic annular diameter
(AVR, 21.6  2.2 mm vs TAVI, 22.8  2.4; P ¼ .014),
despite a similar valve area and similar mean and peak gra-
dients (P¼ .08, P¼ .10, and P¼ .06, respectively, Table 2).
Furthermore, because of the different ‘‘nature’’ of the
compared procedures, AVR were almost always performed
with the patient under general anesthesia, with epiduralery c February 2014
TABLE 2. Baseline characteristics of matched population of patients
with severe left ventricular systolic dysfunction (LVEF  35%)
Variable AVR (n ¼ 81) TAVI (n ¼ 81) P value
Demographic and clinical characteristics
Age (y) 77.6  6.4 77.5  10.3 .92
Female gender 31 (38.3) 27 (33.3) .51
Weight (kg) 70.2  16.7 38.7  14.0 .55
Diabetes 22 (27.2) 24 (29.6) .12
Creatinine (mg/dL) 1.5  1.2 1.5  1.1 .95
Chronic dialysis treatment 4 (4.9) 3 (3.7) .70
Albumin (mg/dL) 3.4  1.0 3.6  0.9 .44
Hemoglobin (mg/dL) 12.1  1.5 11.7  1.8 .15
Previous AMI 9 (11.1) 3 (3.7) .16
Unstable angina 7 (8.9) 3 (3.7) .18
COPD 17 (21.0) 23 (28.4) .27
Oxygen dependency 6 (7.4) 3 (3.7) .30
Neurologic dysfunction 6 (7.4) 5 (6.2) .58
Chronic liver disease 3 (3.7) 3 (3.7) 1.00
Peripheral arteriopathy 18 (22.2) 21 (25.9) .58
Previous cardiac surgery 19 (23.5) 18 (22.2) .85
Previous vascular surgery 3 (3.7) 6 (7.4) .30
Frailty score .70
1 (self-sufficient) 63 (77.8) 65 (80.3)
2 (partially self-
sufficient)
18 (22.2) 16 (19.7)
Previous PCI 17 (25.3) 29 (35.8) .17
Previous aortic balloon
plasty
9 (11.1) 9 (11.1) 1.00
Critical preoperative state 11 (13.6) 12 (14.8) .82
NHYA class .81
III 34 (42.0) 31 (38.3)
IV 15 (18.5) 18 (22.2)
Logistic EuroSCORE 25.9  18.8 21.4  14.3 .10
Angiographic and echocardiographic findings
Coronary artery disease .27
1-vessel 14 (17.3) 22 (27.2)
2-vessel 4 (4.9) 7 (8.6)
3-vessel 14 (17.3) 10 (12.3)
Left main — —
Mitral valve regurgitation .87
None or mild 49 (60.5) 50 (61.7)
Moderate or severe 32 (39.5) 31 (38.3)
Aortic valve pattern
Valve area (cm2) 0.7  0.3 0.6  0.2 .08
Peak gradient (mm Hg) 68.2  24.7 62.2  20.9 .10
Mean gradient (mm Hg) 41.5  16.4 37.0  13.1 .06
Annulus diameter (cm) 21.6  2.16 22.8  2.45 .01
Procedural characteristics
Urgency status .67
Urgent 7 (8.6) 10 (12.3)
Emergent 1 (1.2) 1 (1.2)
Anesthesia <.01
General 80 (98.8) 31 (38.3)
Epidural or local 1 (1.2) 50 (61.7)
Associated coronary
procedure
23 (28.4) 4 (4.9) <.01
(Continued)
TABLE 2. Continued
Variable AVR (n ¼ 81) TAVI (n ¼ 81) P value
Type of TAVI prosthesis —
CV — 49 (60.5)
ELS — 32 (39.5)
Data presented as mean  standard deviation or n (%). LVEF, Left ventricular ejec-
tion fraction; AVR, aortic valve replacement; TAVI, transcatheter aortic valve implan-
tation; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary
disease; PCI, percutaneous coronary intervention; NYHA, New York Health Associ-
ation; CV, CoreValve; ELS, Edwards SAPIEN valve.
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Dand/or local anesthetic techniques prevailing with TAVI
(P ¼ .0001; Table 2). Finally, the AVR patients more
frequently underwent concomitant myocardial revasculari-
zation (28.4% vs 4.9% for TAVI; P ¼ .0001; Table 2).Outcomes in Matched Pairs
When the matched patients were analyzed, neither AVR
nor TAVI proved superior in terms of 30-day mortality,
AMI, stroke, cardiac tamponade, LCOS, and perioperative
peak serum creatinine (P ¼ NS; Table 3). Similarly, the
ICU, ImCU, and hospitalization length of stay were compa-
rable between the 2 groups (Table 3).
AVR resulted in a significantly lower need for PPM
implantation (1.2% vs 13.6% for TAVI; P ¼ .01). In
contrast, TAVI demonstrated a significantly lower need
for transfusions (24.4% vs 76.5% for AVR; P < .01),
despite a comparable mean number of transfusions/patient
(AVR, 4.4  3.8 vs TAVI, 2.8  3.7 U/patient; P ¼ .08;
Table 3), suggesting transfusions were quite uncommon
after TAVI but were substantial—and probably
‘‘massive’’—whenever they occurred.
Finally, when the hemodynamic performance of AVR
was compared with that of TAVI, a significantly greater
postoperative mean gradient was found in the surgical
cohort. In contrast, TAVI showed significantly greater
mild-to-severe residual aortic regurgitation (P < .01;
Table 3).DISCUSSION
The main findings of the present study were that TAVI
is a comparable alternative to AVR, at least in the short
term, for patients with SLVSD, and that both treatments
have acknowledged procedure-specific characteristics,
with a greater incidence of PPM implantation and residual
aortic regurgitation after TAVI and a greater need for
transfusions with slightly greater mean gradients after
AVR.
Despite the widened application of TAVI technology
to an exponential population of patients, few studies
have focused on the effect of TAVI in patients with
SLVSD. Furthermore, these studies have generally
compared the outcomes of patients with low versus normalrdiovascular Surgery c Volume 147, Number 2 571
TABLE 3. Hospital outcomes of matched patients
Variable AVR (n ¼ 81) TAVI (n ¼ 81) P value
Hospital mortality 7 (8.6) 5 (6.2) .37
Perioperative AMI 0 (0) 1 (1.2) .55
Stroke 4 (4.9) 1 (1.2) .36
LCOS 9 (11.4) 5 (6.4) .27
Major vascular complications 0 (0) 1 (1.2) .55
Cardiac tamponade 4 (5.1) 1 (1.2) .17
Peak postoperative
creatinine (mg/dL)
1.8  1.4 1.7  1.4 .57
Transfusions/patient (n) 4.4  3.8 2.8  3.7 .08
ICU length of stay (d) 3 (2.4-3.7) 2 (1.5-2.5) .34
ImCU length of stay (d) 0 (0-0.2) 0 (0-0.2) .94
Hospitalization (d) 14 (13.3-14.7) 11 (8.8-13.2) .51
Favors AVR
PPM implantation (%) 1 (1.2) 11 (13.6) .01
Favors TAVI
Transfusion (%) 62 (76.5) 23 (24.4) <.01
Echocardiographic findings
Mean transprosthetic
gradient (mm Hg)
14.5  8.3 9.6  5.5 <.01
Aortic regurgitation <.01
Mild 13 (16.0) 36 (44.4)
Moderate-to-severe 7 (8.6) 5 (6.2)
Data presented as n (%), median (95% confidence interval), or mean  standard de-
viation. AVR, Aortic valve replacement; TAVI, transcatheter aortic valve implantation;
AMI, acute myocardial infarction; LCOS, low cardiac output syndrome; ICU, inten-
sive care unit; ImCU, intermediate care unit; PPM, permanent pacemaker.
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DLVEF.4,5,7,13,14 Direct comparisons with AVR populations
have rarely been reported and have usually been through
retrospective analysis of ‘‘historical’’ surgical populations
with case-control matching.6 A recent study reported the
2-year results of the randomized PARTNER trial, with the
advantages of randomization8 but lacking the mirror of
‘‘real world’’ practice, which can only come from registry
data. Furthermore, some of those studies indirectly derived
the preoperative systolic dysfunction from the recognition
of low-flow, low-gradient SAS.8,13,14 Finally, most of
them were single-center13 or 2-center4-7 studies.
Thus, the present study represents the first direct compar-
ison of AVR and TAVI in a cohort of patients with SLVSD,
whose baseline potential confounding factors were elimi-
nated using nonparsimonious propensity matching. More-
over, the analysis used data from a multicenter
contemporary registry enrolling ‘‘all-comers’’ from ‘‘real-
world’’ practice.9-11
The main finding of the present study was that hospital
mortality was not different between AVR and TAVI in
patients with SLVSD, confirming the subgroup analysis of
patients with a LVEF<55% in PARTNER trial A, which
preliminary reported comparable 1-year survival between
AVR and TAVI.15 However, additional investigations
of patients with severe ventricular dysfunction were
lacking in PARTNER trial A.15 The recent report from
PARTNER trial A addressing the best treatment option in572 The Journal of Thoracic and Cardiovascular Surgthis high-risk category of patients considered all patients
with low-flow aortic stenosis, regardless of the degree of
systolic dysfunction.8 It also did not differentially analyze
patients with low-flow aortic stenosis, those with low-flow
aortic stenosis and a low LVEF, and those with low-flow,
low-gradient, and low LVEF.8 Furthermore, a ‘‘high’’
threshold of LVEF of 50% was considered the cutoff to
define systolic dysfunction in PARTNER trial A.8,15
Similarly, a recent 2-center European study reported a com-
parable 1-year outcome of AVR and TAVI in patients with
LVEF<50%.6 The same study demonstrated a comparable
procedural success rate and in-hospital and 1-year survival
between patients with a normal and depressed LVEF under-
going TAVI, with only lower 1-year freedom from cumula-
tive cardiovascular events in patients with a LVEF<50%
after TAVI.6 Furthermore, some studies analyzing the
outcome of TAVI with and without SLVSD demonstrated,
not only comparable mortality, but also similar major
morbidity.4-7 In more detail, Pilgrim and colleagues4
showed a similar incidence of myocardial infarction, major
stroke, life-threatening bleeding, major access site compli-
cations, valvular reintervention, and renal failure at 30 days.
van der Boon and colleagues5 showed a comparable com-
bined safety endpoint, including myocardial infarction,
cerebrovascular events, vascular and bleeding complica-
tions, and acute kidney injury. Ewe and colleagues6
reported a similar incidence of stroke, heart failure, and
cardiovascular events during hospitalization. Fraccaro and
colleagues7 demonstrated a comparable incidence of
AMI, stroke, acute kidney injury, and sepsis. Finally, the
German multicenter registry reported a comparable cere-
brovascular events rate in patients undergoing TAVI with
or without low-flow, low-gradient SAS but also a greater
incidence of low output syndrome in the former subgroup.14
All these studies also reported the efficacy of TAVI in terms
of the risk of major morbidity in the subset of patients with a
low LVEF. Thus, with that perspective and given the lack of
published data directly comparing the 2 techniques of valve
replacement in terms of morbidity, we can interpret our data
as underscoring a substantial equipoise between AVR and
TAVI in terms of major morbidity (AMI, stroke, cardiac
tamponade, LCOS, and perioperative peak serum creati-
nine). Accordingly, it was not surprising that the ICU,
ImCU, and hospitalization stay were also comparable
between the 2 procedures in the matched patients with a
similar risk profile. The published data have generally
favored TAVI versus AVR in terms of the ICU length
of stay15,16 and hospitalization.15,17 However, it has been
demonstrated that differences in terms of the baseline
characteristics, institutional protocols for ICU, ImCU, and
hospital admission and discharge, and periprocedural
complications of the individual studies can significantly
affect the length of stay after the 2 procedures.10-15,17
Hence, a substantial similarity in terms of hospitalizationery c February 2014
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Dhas been reported in a recent propensity-matched German
experience comparing AVR and TAVI and also resulting
in similar hospital outcomes.16We have previously reported
similar lengths of hospitalization and ICU stays in 2 ana-
lyses of the OBSERVANT registry, with 1 investigating
an intermediate-risk propensity-matched population9 and
1, a propensity-matched female population undergoing
AVR versus TAVI.10 Therefore, the present data have
confirmed that similar baseline risk profiles and similar hos-
pital mortality and major morbidity will also result in
similar ICU, ImCU, and hospital lengths of stay. These
data should also be interpreted in light of the supposed
superiority of TAVI in terms of cost-effectiveness and
length of hospitalization.
AVR resulted in a greater rate of periprocedural transfu-
sions despite a similar transfusion need/patient. The ‘‘com-
mon’’ need for transfusions after surgery is well-known and
is intrinsically related to the need for cardiopulmonary
bypass, with its hemodilution, generation of thrombin,
inflammatory reaction, postoperative bleeding, and so
forth.18 A low preoperative hemoglobin and older age
have been reported to predict the need for transfusion after
AVR.19 Aortic valve stenosis has also been recognized as a
hemodynamic condition whose related shear stress favors
an acquired von Willebrand syndrome, affecting platelet
function and hemostasis.20 Moreover, different series
comparing AVR and TAVI have previously reported a
greater transfusion rate after surgery,9,16 especially in
female patients.10 All these data, together with a relatively
low preoperative hemoglobin level and relatively greater
prevalence of women in our AVR propensity-matched pop-
ulation, could help to explain that finding. The number of
transfusions/patient did not differ between the 2 groups,
suggesting that transfusions were quite uncommon after
TAVI but were ‘‘substantial’’ at the least when required.
The 1.2% incidence of major vascular complications in
our TAVI series (compared with a 0% incidence with
AVR) might explain this finding, owing to the demonstra-
tion of a strict relationship between major vascular compli-
cations or disabling bleeding and the need for massive
transfusions after TAVI.21 The same correlation has been
previously reported in another OBSERVANT subanalysis.11
These data underscore the urgent need for advances in blood
management after surgery and for an improved ‘‘design’’ of
TAVI prostheses to reduce the risk of major vascular
complications.
However, TAVI resulted in a greater need for PPM
implantation than did AVR. The need for PPM implantation
is a well-known Achilles’ heel of TAVI procedures. It has
been reported to occur in 15.6% of the French population
enrolled in the French Transcatheter Aortic Valve Interven-
tion (FRANCE-2) study.22 Also, in studies investigating a
low LVEF population, PPM implantation was required in
18%, 26%, and 27% of patients with SLVSD.4,5,7 WeThe Journal of Thoracic and Cahave also previously reported that female gender was an
independent predictor of the avoidance of PPM after
TAVI,11 suggesting that the prevalence of male gender
(66.6%) in the present cohort of propensity-matched
TAVI patients favored the need for PPM implantation.
Moreover, different studies have reported the CoreValve
prosthesis (Medtronic, Minneapolis, Minn) to be associated
with a significantly greater need for PPM implantation
owing to its intrinsic design with the stent directly
impinging on the membranous septum and the left ventric-
ular outflow tract.17,22-24 Again, the 66.7% prevalence of
CoreValve (Medtronic) use in the present TAVI cohort
explains our 13.6% rate of PPM implantation. Finally, we
have confirmed the results of the only published report
specifically comparing AVR and TAVI in terms of PPM
need, which clearly reported a lower periprocedural
development of complete atrioventricular block after
surgery.17
Finally, when the hemodynamic behavior of AVR and
TAVI was compared, AVR resulted in an average 5 mm
Hg greater mean transprosthetic gradient compared with
TAVI, confirming our previous experience9,10 and that of
others.17,24 These gradients reflect the different nature
between surgical and percutaneous prostheses, with the
former preferentially ‘‘stented’’ and the latter exclusively
‘‘stentless,’’ without any sewing line and with the need for
iatrogenic distension of the aortic annulus by systematic
oversizing.24 Whether a slightly greater mean gradient in
the absence of patient–prosthesis mismatch might affect
the outcomes requires long-term outcomes data to deter-
mine. Similarly, the greater residual postprocedural aortic
regurgitation observed in the TAVI cohort (about 50% of
the patients with SLVSD demonstrated mild-to-severe post-
procedural regurgitation) requires long-term data to analyze
its effect on the outcomes. Nevertheless, postprocedural
regurgitation is another well-known Achilles’ heel of
TAVI. Significant postprocedural regurgitation was
observed in 64.5% of TAVI patients in the FRANCE-2 reg-
istry.22 A recent comprehensive review of the PARTNER
trial reported that paravalvular leak after TAVI was associ-
ated with increased mortality, even when mild.25 Of utmost
importance, Fraccaro and colleagues,7 specifically
analyzing the population of patients with SLVSD undergo-
ing TAVI, reported greater mortality in patients with ven-
tricular dysfunction and found it to be significantly
affected by residual moderate-to-severe residual aortic
regurgitation. Finally, regarding the need for PPM implan-
tation, the CoreValve prosthesis (Medtronic) has also been
reported to induce greater postprocedural aortic regurgita-
tion than Edwards SAPIEN valves (Edwards Lifesciences,
Irvine, Calif),26 thus suggesting a prosthetic-related wors-
ening of outcome in terms of residual regurgitation in our
TAVI cohort. However, despite the need for long-term
data, in particular to address the specific effect of mildrdiovascular Surgery c Volume 147, Number 2 573
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Dresidual regurgitation on outcome, the reported different
hemodynamic profile of AVR and TAVI in our patients
with SLVSD did not affect the 30-day mortality, 30-day
incidence of LCOS, or the ICU, ImCU, or hospital lengths
of stay. However, additional studies addressing these topics
are warranted.
It was surprising that AVR did not perform better than
TAVI in patients with a LVEF of 35% when only
moderate-to-severe postprocedural aortic regurgitation
was considered. That unexpected finding was new in our
experience, given that a significant superiority of AVR
over TAVI in terms of that endpoint has been previously
reported in several OBSERVANT studies comparing a
propensity-matched, intermediate-risk population,9 a
propensity-matched female population,10 or gender-
related differences in risk profiles and outcomes.11 A recent
study comparing AVR and TAVI for patients with a reduced
LVEF has confirmed the well-known notion that AVR
significantly reduces the aortic regurgitation grade
compared with baseline, a finding not confirmed after
TAVI.27 However, a mean postoperative aortic regurgitation
grade of 0.5  0.3 after AVR was also reported in that
study.27 Furthermore, a report from the Veterans Affairs
Hospital clearly revealed that postoperative residual regur-
gitation after standard AVR is more common than expected
(13% of aortic regurgitation of any degree in their study),
especially when severe calcifications are encountered, after
biologic prosthesis placement, in aged patients, or in those
with a small body surface area,28 all typical features of any
contemporary frail and elderly population undergoing AVR,
such as the population included in the present study. A
recent Canadian surgical experience also confirmed the
nonrare occurrence of residual regurgitation after standard
AVR and its prognostic significant on survival when se-
vere.29 Although an ‘‘imbalance’’ toward the ‘‘worst AVR
patients’’ could not be excluded in the present study
because of the use of propensity score matching (which
‘‘couples’’ AVR patients to similar TAVI patients), this
unexpected finding deserves additional investigation. It
also requires investigation because of the anticipated supe-
riority of AVR over TAVI in terms of moderate-to-severe
postprocedural aortic regurgitation.
Study Limitations
The main limitation of the present study was related to the
observational nature of the OBSERVANT registry. Evalu-
ating the effect of a specific treatment using a registry can
lead to incorrect conclusions because of the influence of
unknown confounding variables. However, treatment was
not assigned randomly but after evaluation by a multidisci-
plinary local ‘‘heart team,’’ as suggested by current guide-
lines.12 This policy could still have generated an
unavoidable risk of bias regarding treatment selection.
Also, no standardized protocols for cardiopulmonary bypass574 The Journal of Thoracic and Cardiovascular Surgor anesthetic techniques were used because of
the observational nature of the registry.9-11 Also, details on
preoperative stratification, treatment allocation, techniques
used (eg, surgery or TAVI, transfemoral vs nontransfemoral
routes, choice of surgical and percutaneous valves),
definition of outcome variables, postprocedural medical
management, data management, and quality control of the
registry have all been previously reported.9-11 In contrast,
registries are considered the ‘‘real-world’’ mirror of current
practice, and their results have witnessed the contemporary
outcomes after TAVI and AVR in so-called all-comer
patients. Moreover, the nonparsimonious propensity-
matched analysis used in the present study has significantly
contributed to attenuate the potential bias. Finally, the
absence in published data of direct comparisons between
AVR and TAVI in ‘‘all-comer’’ patients with SLVSD has
emphasized the significance of these preliminary results.
The endpoints were not perfectly stringent with the
VARC/VARC-2 criteria.12 In particular, we did not detail
the causes of mortality according to the VARC-2 criteria,12
because the individual causes of death could not be pre-
cisely identified from the registry. However, 30-day mortal-
ity has been universally recognized as mortality directly
related to the index procedure; thus, it could be considered
similar to the recently defined ‘‘procedural mortality’’ of
the VARC-2 criteria.12 When the OBSERVANT registry
was launched, neither the VARC nor VARC-2 criteria
were available.12 Furthermore, the VARC definitions were
specifically designed to define the complications after
TAVI; therefore, an overestimation of adverse events in
the AVR population could have occurred.9-12CONCLUSIONS
Our study has demonstrated that both AVR and TAVI can
achieve good results in patients with SLVSD, without any
technique-related early substantial survival benefit. Also,
in this subgroup of patients, the original weaknesses of
both procedures have been confirmed. These weaknesses
include the cardiopulmonary bypass-related hemodilution
and inflammation cascade—with its consequent need for
transfusions—for the surgical cohort and the excessive
need for PPM implantation and the still high prevalence
of residual regurgitation, the effect of which on severely
depressed ventricles could become detrimental over time
for the TAVI cohort. From our experience and the compara-
ble results, the presence of SLVSD should not represent, on
its own, an argument to shift a patient with SAS considered
for surgery to TAVI.References
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